Use of the Start- stopp in Belgium to screen elferly patient's treatments. Datao of teh WOrking Group Clinical Pharmacology , Pharmacotherapy and Pharmaceutical Care
Dalleur, O × Baeyens, H Boland, B De Lepeleire, Jan Evin-Adin, E Gilles, C Pepersack, T Petrovic, M Somers, A Spinewine, A Van Nes, MC #
Tijdschrift voor Gerontologie en Geriatrie vol:43 issue:1 pages:46-47
Wintermeeting BVGG location:Oostende date:2-3 maart 2012
Purpose: STOPP and START are recent screening tools to detect over/mis-prescription and underprescription
respectively in elderly patients. Their use is growing among clinicians because they present
advantages over other existing tools: link between clinical situations and evidence-based use of drugs; easy
The objective is to describe studies on STOPP&START led by members of the Working Group "Clinical
Pharmacology, Pharmacotherapy and Pharmaceutical care” (WG).
Methods: Observational survey on the results of the WG members who accepted to share their data.
Results: 4 retrospective and 1 prospective studies were identified. Overall, 1219 patients'treatments
(81,4 years, 7 drugs/day) were screened with STOPP&START. Studies included patients from several
settings (primary or secondary care, geriatric patients hospitalized in geriatric units or in other units). 3
studies assessed treatment at home while 2 studies compared treatment before admission and at discharge.
Although these studies are difficult to compare because of differences in settings and designs, the
drugs most frequently detected with the tools are relatively similar across all studies. STOPP mainly
highlights overuse of drugs affecting fallers and belonging to the neurologic system (mainly
benzodiazepines). START shows under-prescription of cardiovascular secondary prevention (mainly aspirin
and statins) and osteoporosis treatments. These results are consistent with a recent international
multicentric study on STOPP and START.
Conclusions: STOPP&START have been used recently in various settings in Belgium. Inappropriate
prescription patterns seem to be similar across the country as the most frequently inappropriate drugs
detected are comparable between studies. The WG invites other clinicians to join the group and share data
in the future.